Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILINGPoster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI ...

Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.7 while the S&P 500 average is 29.3 Its forward ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

The recent formation of the FIBRE Consortium, a collaboration involving Pfizer (NYSE:PFE) and other pharmaceutical partners, ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

My final reason for buying more Pfizer stock is that I'll get paid nicely to wait and see if the drugmaker lives up to Wall Street's growth outlook. Pfizer's forward dividend yield currently stands at ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Sector-by-sector analysis throws a spotlight on high-yielding winners in more defensive areas of the stock market.

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...